Ocular Therapeutix (OCUL) EBITDA (2013 - 2026)
Ocular Therapeutix (OCUL) EBITDA from Jun 30, 2013 to Mar 31, 2026. The TTM Ocular Therapeutix (OCUL) EBITDA is -$295M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Ocular Therapeutix (OCUL) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +47.23% |
| 3 Years TTM | +53.61% |
| 5 Years TTM | +35.83% |
| 10 Years TTM | +21.87% |
| All Time TTM | +27.95% |
Annual EBITDA change of Ocular Therapeutix (OCUL)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$92M | -65.35% |
| 2025 | -$266M | +58.16% |
| 2024 | -$168M | +111.57% |
| 2023 | -$79M | +3.74% |
| 2022 | -$77M | +1.22% |
| 2021 | -$76M | +25.89% |
| 2020 | -$60M | -27.86% |
| 2019 | -$83M | +46.52% |
| 2018 | -$57M | -5.75% |
| 2017 | -$60M | +42.08% |
| 2016 | -$42M | +13.35% |
| 2015 | -$37M | +41.02% |
| 2014 | -$27M | +112.40% |
| 2013 | -$13M | -5.80% |
| 2012 | -$13M | N/A |
Comparison Ocular Therapeutix (OCUL) five years EBITDA CAGR with competitors
Ocular Therapeutix (OCUL) five years EBITDA CAGR is 35.82%.